Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits

被引:13
作者
Candas, B
Labrie, F
Gomez, JL
Cusan, L
Chevrette, E
Lévesque, J
Brousseau, G
机构
[1] Laval Univ Hosp, Mol Endocrinol & Oncol Res Ctr, Res Ctr, Ctr Hosp, Quebec City, PQ G1V 4G2, Canada
[2] Laval Univ Hosp, Dept Med, Res Ctr, Quebec City, PQ, Canada
[3] Laval Univ Hosp, Ctr Hosp, Prostate Canc Clin, Quebec City, PQ, Canada
[4] Univ Laval, Dept Physiol & Anat, Quebec City, PQ G1K 7P4, Canada
[5] Laval Univ Hosp, Dept Radiol, Res Ctr, Laval, PQ, Canada
关键词
prostate; prostatic neoplasms; mass screening; prostate-specific antigen;
D O I
10.1016/S0022-5347(05)00165-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the probability of positive serum PSA (3 ng/ml or greater) and CaP detection at annual followup visits in men with negative initial PSA (less than 3 ng/ml) to optimize the re-screening schedule. Materials and Methods: Data on 5,387 men 45 to 80 years old with negative PSA and no CaP diagnosis at the first screening visit were obtained from the Laval University Prostate Cancer Screening Program database. Accelerated failure time regressions were fitted to time from baseline to positive PSA and to time from positive PSA to CaP detection. The models were combined to estimate the cumulative probability of positive PSA followed by CaP detection at re-screening. Results: The 5-year cumulative probability of detecting CaP at annual visits in men with baseline PSA up to 1.5 ng/ml remained below 0.8%, while it was 1.3%, 4.8% and 8.3% in men with PSA 1.5 to less than 2, 2 to less than 2.5 and 2.5 to less than 3 ng/ml, respectively. Time to positive PSA significantly decreased with increasing baseline PSA and age, while the time between positive PSA and CaP detection depended only on age. Men with PSA below 1.0 ng/ml could wait for 4 to 5 years before being re-tested, while men with PSA between 1.0 and 1.5 ng/ml should be screened every second year and men with PSA 1.5 ng/ml or greater should be screened every year. Conclusions: The proposed retesting schedule using current PSA and age decreases the number of visits by 38.1%, while delaying the detection of only 2.4% of CaPs that would have been detected using annual PSA testing.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 20 条
  • [1] Candas B, 2000, PROSTATE, V45, P19
  • [2] CRAWFORD D, 2001, J UROL S, V167, P99
  • [3] Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
    de Koning, HJ
    Auvinen, A
    Sanchez, AB
    da Silva, FC
    Ciatto, S
    Denis, L
    Gohagan, JK
    Hakama, M
    Hugosson, J
    Kranse, R
    Nelen, V
    Prorok, PC
    Schröder, FH
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) : 237 - 244
  • [4] Total and transition zone prostate volume and age: How do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan, B
    Zlotta, AR
    Remzi, M
    Ghawidel, K
    Bursa, B
    Hruby, S
    Wolfram, R
    Schulman, CC
    Marberger, M
    [J]. UROLOGY, 1999, 54 (05) : 846 - 852
  • [5] Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded:: A prospective study of 510 patients
    Gjengsto, P
    Halvorsen, OJ
    Akslen, LA
    Frugård, J
    Hoisaeter, PA
    [J]. UROLOGY, 2003, 62 (03) : 447 - 450
  • [6] PROSTATE-CANCER SCREENING IN THE PROSTATE, LUNG, COLORECTAL AND OVARIAN-CANCER SCREENING TRIAL OF THE NATIONAL-CANCER-INSTITUTE
    GOHAGAN, JK
    PROROK, PC
    KRAMER, BS
    CORNETT, JE
    [J]. JOURNAL OF UROLOGY, 1994, 152 (05) : 1905 - 1909
  • [7] Pathologic features of prostate cancer found at population-based screening with a four-year interval
    Hoedemaeker, RF
    van der Kwast, TH
    Boer, R
    de Koning, HJ
    Roobol, M
    Vis, AN
    Schröder, FH
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (15) : 1153 - 1158
  • [8] Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
    Hugosson, J
    Aus, G
    Lilja, H
    Lodding, P
    Pihl, CG
    Pileblad, E
    [J]. JOURNAL OF UROLOGY, 2003, 169 (05) : 1720 - 1723
  • [9] Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer
    Ito, K
    Yamamoto, T
    Ohi, M
    Takechi, H
    Kurokawa, K
    Suzuki, K
    Yamanaka, H
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) : 455 - 460
  • [10] The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less
    Ito, K
    Yamamoto, T
    Suzuki, K
    Kurokawa, K
    Yamanaka, H
    [J]. JOURNAL OF UROLOGY, 2004, 171 (02) : 656 - 660